Sporadic Creutzfeldt-Jakob disease (sCJD), the most common human prion disease, is transmissible through iatrogenic routes due to abundant infectious prions [misfolded forms of the prion protein (PrP Sc )] in the central nervous system (CNS). Some epidemiological studies have associated sCJD risk with non-CNS surgeries. We explored the potential prion seeding activity and infectivity of skin from sCJD patients. Autopsy or biopsy skin samples from 38 patients [21 sCJD, 2 variant CJD (vCJD), and 15 non-CJD] were analyzed by Western blotting and real-time quaking-induced conversion (RT-QuIC) for PrP Sc . Skin samples from two patients were further examined for prion infectivity by bioassay using two lines of humanized transgenic mice. Western blotting revealed dermal PrP Sc in one of five deceased sCJD patients and one of two vCJD patients. However, the more sensitive RT-QuIC assay detected prion seeding activity in skin from all 23 CJD decedents but not in skin from any non-CJD control individuals (with other neurological conditions or other diseases) during blinded testing. Although sCJD patient skin contained~10 3 -to 10 5 -fold lower prion seeding activity than did sCJD patient brain tissue, all 12 mice from two transgenic mouse lines inoculated with sCJD skin homogenates from two sCJD patients succumbed to prion disease within 564 days after inoculation. Our study demonstrates that the skin of sCJD patients contains both prion seeding activity and infectivity, which raises concerns about the potential for iatrogenic sCJD transmission via skin.
INTRODUCTION
Prion diseases are fatal, transmissible spongiform encephalopathies (TSEs) that affect humans and other animals. They are associated with the deposition of misfolded forms of the prion protein (PrP Sc ) in the central nervous system (CNS) that propagate by seeding the multimerization and conformational conversion of normal cellular prion protein (1) . These misfolded PrP conformers are the primary constituent of infectious TSE agents (prions).
Human prion diseases include Creutzfeldt-Jakob disease (CJD), fatal insomnia, Gerstmann-Sträussler-Scheinker syndrome, kuru, and variably protease-sensitive prionopathy (2) . The etiology can be sporadic, acquired by infection, or inherited. Although phenotypically heterogeneous, prion diseases are clinically characterized by varying degrees of dementia, myoclonus, extrapyramidal signs, cerebellar ataxia, and pyramidal signs and pathologically characterized by spongiform degeneration, neuronal loss, and astrocytosis in the brain. The most common form of human prion disease, sporadic CJD (sCJD), usually has a rapid and dramatic clinical course with a mean duration of less than 6 months. More than six subtypes of sCJD can be differentiated on the basis of their clinical phenotypes, together with the polymorphic residue at codon 129 of PrP Sc [Met/Met (MM), Val/Val (VV), or Met/Val (MV)], and distinct or coexisting PrP Sc types (1 or 2) associated with different amino terminal protease cleavage sites (3) . sCJD is transmissible iatrogenically, for example, via CNS-associated or cornea-associated surgical operations, or injections of brain-derived contaminated growth hormone and gonadotropins (4) . Some epidemiological observations have suggested that the risk of sCJD may even be associated with a history of having various non-CNS-related surgeries, the number of surgeries, and the age at the time of the first surgery (5) (6) (7) (8) .
A case-control study also reported that statistically significant odds ratios were obtained for injury to (or surgery on) the head, face, or neck and trauma to other parts of the body (9) . However, other studies reported little correlation between surgeries and sCJD incidence (10, 11) .
Although the involvement of the skin in sCJD infections remains unclear, proteinase K (PK)-resistant PrP Sc was detected in the skin of a single patient with variant CJD (vCJD) (12) , a distinct CJD strain that originated from exposure to bovine spongiform encephalopathy. Here, using Western blotting (13) , real-time quaking-induced conversion (RT-QuIC) assay (14) , and bioassay with humanized transgenic (Tg) mice (15), we tested for PrP Sc and prion infectivity in skin samples from patients with sCJD.
RESULTS

CJD patient clinical information and detection of PrP Sc in brain tissue
Skin tissues were collected at autopsy or by biopsy from 38 subjects, including patients with sCJD or vCJD, as well as from non-CJD control individuals with or without other neurological conditions (Table 1 and  table S1 ) (16, 17) . Both skin and brain tissues were collected from 30 of the 38 subjects, including cases with sCJD (n = 21), vCJD (n = 2), and non-CJD patients with other neurological conditions (n = 7). The demographic and clinical features of the patients with either sCJD or vCJD are summarized in Table 1. The demographic characteristics  and diagnoses of non-CJD controls are provided in table S1. Patients  with sCJD had either MM, MV, or VV polymorphisms at residue  129 of the PrP sequence and either type 1, type 2, or coexisting types  1 and 2 PrP  Sc (sCJDMM1, sCJDMM2 , sCJDMV1, sCJDMV2, sCJDVV1, sCJDVV2, sCJDMV1-2, sCJDVV1-2, or sCJDMM1-2), as determined by Western blotting and histology of brain tissues (3) . Western blotting and neurohistology detected PrP Sc and spongiform degeneration in the brains of all of the CJD cases but not in the non-CJD controls ( fig. S1 shows examples of brain tissue from five sCJD, two vCJD, and two non-CJD patients).
Detection of PrP
Sc in the skin by Western blotting and immunohistochemistry Previously, PrP Sc was barely detectable by Western blotting in a skin sample collected postmortem from the torso area of a vCJD patient after enrichment with sodium phosphotungstate precipitation (12, 17) . We first examined skin samples from the torso of the same vCJD patient from the United States (US vCJD) and from the forearm of another vCJD patient from the United Kingdom (UK vCJD) using an approach that previously succeeded in enriching and detecting PrP Sc in the skin of animals naturally and experimentally infected with scrapie (13) . After a series of ultracentrifugation steps followed by PK treatment, the PKtreated, PrP Sc -concentrated fraction (termed P4) was obtained. PrP Sc was detectable in the US vCJD patient P4 sample on Western blots probed with the anti-PrP antibody 3F4 against human PrP(96-112) or anti-C antibody against human PrP(220-231) after treatment with PK with or without peptide N-glycosidase F (PNGase F) (Fig. 1, A and B) , consistent with the previous study (12) . However, no PrP Sc was detected in the skin of the UK vCJD patient after the same treatment (Fig. 1C) . The amount of brain PrP Sc in the two vCJD cases was compared by Western blotting, and a six-to sevenfold lower amount was found in the UK patient than in the U.S. patient by quantitative densitometric analysis (Fig. 1D) .
Using the same method, we next examined the PrP Sc -enriched skin samples (P4 fraction) from the apex (top of the head), an area next to the ear, or other body areas including the forearm, torso, or leg of 5 confirmed sCJD patients and 10 non-CJD controls, using the US vCJD skin as a positive control. After PK treatment, no PK-resistant PrP was detectable in any of the non-CJD and sCJD skin samples except for one sCJD case (patient no. 5), who exhibited very faint bands that were much weaker than those shown in the vCJD skin sample positive control (patient no. 6) (Fig. 1E, top) . To increase sensitivity, we treated enriched preparations with both PK and PNGase F before Western blot analysis using anti-C antibody, as previously described (18) . Only the skin sample from patient no. 5 produced a deglycosylated PrP Sc band that co-migrated with the corresponding vCJD band (Fig. 1E, bottom) . Moreover, the intensity of this PrP band was about four-to fivefold lower in the sCJD skin sample than in the US vCJD skin sample positive control (Fig. 1E) , as measured by densitometric analysis of the protein bands. These results indicated that the amount of PK-resistant PrP Sc in the skin tissues of sCJD patients was either low or undetectable in most cases by Western blotting.
Compared to the US vCJD case, the UK vCJD patient exhibited no Western blotting-detectable PrP Sc in the skin and also a six-to sevenfold lower amount of PrP Sc in brain tissue (Fig. 1D ), which may be associated with a shorter disease duration in the UK case (18 months for the UK vCJD patient versus 34 months for the US vCJD patient). In sCJD patients, it has been reported that the higher amounts of brain 
PrP
Sc in sCJD type 2 than in sCJD type 1 could be associated with the longer disease duration in the former than in the latter (19) . Notably, the PrP Sc from the UK case showed a doublet middle band and an unglycosylated PrP band that migrated slightly higher than that of the US vCJD case. A similar middle band variation has been reported in vCJD and sCJD by Head et al. (20) . However, it is unclear why the lower PrP band migrated slower in the UK case than in the U.S. case, although the clinical history and neuropathology of this case were typical for the vCJD diagnosis. In addition, immunohistochemistry of skin samples from the two vCJD and two sCJD patients, as well as two non-CJD controls, also revealed no specific PrP Sc staining with the anti-PrP antibody 3F4 ( fig. S2 with examples of two vCJD and one non-CJD patient samples).
Detection of prion seeding activity in CJD patient skin samples by RT-QuIC assay As another approach to detect PrP Sc in sCJD skin samples, we used the ultrasensitive RT-QuIC assay. This assay uses the amyloid-sensitive fluorescent dye, thioflavin T (ThT), to monitor PrP Sc -seeded formation of amyloid fibrils from a purified recombinant PrP substrate (14, (21) (22) (23) . The same skin extracts, prepared and tested by Western blotting at the Case Western Reserve University (CWRU), were coded and examined blinded by RT-QuIC at the Rocky Mountain Laboratories. A 10 −3 dilution of either the first supernatant (S1) or the final PK-digested and PrP Sc -enriched pellet (P4) of the skin extraction sample, as well as a 10 −5 dilution of brain homogenate from the same patients, was assayed using recombinant bank vole PrP (rPrP sen ) as the substrate ( Fig. 2A) . As expected (14, 22, 23) , the sCJD and vCJD brain samples all elicited strong and rapid positive RT-QuIC responses. Clear seeding activity was also observed in all skin S1 and P4 fractions from the CJD patients. By contrast, no prion seeding activity was observed in the brain or the skin S1 or P4 extracts from any of the 10 non-CJD control patients, showing that the seeding activity in the CJD patients' brain and skin samples was disease-specific ( Fig. 2A ). These findings were further confirmed by blinded testing of S1 fractions from skin collected from the lower back, skull apex, and an area near the ear of each of 21 additional cases that included 16 sCJD and 5 non-CJD cases (Fig. 2 , B and C). Our results showed that all of the CJD patients had at least one RT-QuICpositive skin sample (Fig. 2 , B and C, and Table 2 ). However, no single skin location was always RT-QuIC-positive. Of the three skin areas, the area near the ear had the highest and most consistent prion seeding activity (Fig. 2 , B and C), that is, in 94% of sCJD cases (Table 2) .
To assess the prion seeding activity in the S1 and P4 skin fractions compared to brain homogenates from the same patients, we performed RT-QuIC end point dilution analyses. Figure S3 shows representative data from vCJD and sCJD patients. Table 3 provides a summary of the calculated 50% seeding dose (SD 50 ) per milligram of tissue from each brain and skin sample of five patients with sCJD and two patients with vCJD. Relative to brain concentrations of 10 8.0 to ≥10 9.7 SD 50 per milligram of tissue, the S1 skin fractions for sCJD patients contained 10 5.0 to 10 6.9 SD 50 per milligram of tissue equivalent, whereas the P4 fractions had 10 3.0 to 10 4.9 SD 50 per milligram of tissue equivalent. Our analysis showed that the average prion seeding activity in sCJD S1 or P4 skin fractions was~10 3 -to 10 5 -fold lower than in the corresponding brain tissue samples.
Discrimination of prion seeding activity by RT-QuIC in sCJD and vCJD patient skin samples To further investigate the different seeding capabilities present in skin extracts from sCJD and vCJD patients, we analyzed P4 skin fractions from the sCJD and vCJD patients using a second rPrP sen substrate, hamster rPrP sen (residues 23 to 231), which was previously shown to help discriminate between these two human prion strains from brain tissues (21) . PrP Sc in both sCJD and vCJD skin samples could be amplified by bank vole rPrP sen substrate (Fig. 3A) , but only the sCJD skin samples gave positive reactions with the hamster rPrP sen substrate (Fig.  3B) . However, the P4 skin fractions from sCJD patient no. 3 and vCJD patient no. 7 were not included in this analysis because of the low amount of prion seeding activity that diminished the reliability of discrimination between the two strains. Nevertheless, these results provide further evidence that, as we described previously for brain samples, sCJD and vCJD seeding activities in skin could be discriminated by comparing differential RT-QuIC responses with bank vole and hamster rPrP sen substrates, provided that the seeding activities detected with the bank vole rPrP sen substrate were not close to the detection limit. Western blot analyses of the products of RT-QuIC reactions with the bank vole rPrP sen substrate revealed variable patterns of PK-resistant reaction products; however, it was not apparent that such patterns would aid additionally in CJD strain or type discrimination ( fig. S4 ).
Prion infectivity in skin samples from sCJD patients detected in humanized Tg mice To determine whether skin from sCJD patients was infectious, we conducted a bioassay using two lines of humanized Tg mice (TgNN6h and TgWV), which were generated in our laboratories previously. TgNN6h mice express human PrP-129M with the two N-linked glycosylation sites mutated to eliminate glycosylation (24), whereas TgWV mice express wild-type human PrP-129V (25) . We observed that TgNN6h and TgWV mice were susceptible to sCJDMM2 or sCJDVV2 prion strains, respectively, after an intracerebral inoculation of 129 polymorphism-matched sCJD brain homogenates; this was confirmed by Western blotting (fig. S5 ). TgNN6h mice (n = 7) each inoculated intracerebrally with 30 ml of 1% brain homogenate from a sCJDMM2 patient developed prion disease at an average of 263 ± 25 (SD) days post inoculation (dpi) (range, 164 to 368 dpi). By contrast, TgWV mice (n = 5) each inoculated intracerebrally with 30 ml of 1% brain homogenate from a sCJDVV2 patient succumbed to the disease at an average of 157 ± 11 (SD) dpi (range, 150 to 177 dpi). Given these studies, five TgNN6h mice and seven TgWV mice were inoculated intracerebrally with 30 ml of 5% skin tissue homogenate from a sCJDMM2 case (patient no. 4; Table 3 ) or a sCJDVV1 case (patient no. 1; Table 3 ), respectively. All five TgNN6h mice inoculated with the sCJDMM2 skin homogenate developed a hunched back, ruffled fur, and lethargy/slow movements after an average of 370 ± 51 (SD) dpi (range, 300 to 417 dpi) (Fig. 4A) ; these signs were very similar to those observed in TgNN6h mice inoculated with sCJDMM2 brain homogenate. We also detected PKresistant PrP
S C I E N C E T R A N S L A T I O N A L M E D I C I N E | R E S E A R C H A R T I C L E
Sc and spongiform degeneration in the brains of these TgNN6h mice (Fig. 4, B and D) . All seven TgWV mice inoculated with sCJDVV1 skin homogenate became infected at an average of 436 ± 80 (SD) dpi (range, 332 to 564 dpi) (Fig. 4A) , as confirmed by Western blotting and neurohistology (Fig. 4, C and E) . The TgWV mice mostly exhibited slow movements and weight gain and had detectable PK-resistant PrP Sc and spongiform degeneration in the brain (Fig. 4E) . The gel migration pattern of PrP Sc detected in the brains of mice inoculated with sCJD skin samples was very similar to that of PrP Sc from mice inoculated with sCJD brain tissue, suggesting that at least some of the prion strain-specific biochemical features of the inocula were maintained (Fig. 4C) . Moreover, the profiles of spongiform degeneration and PrP staining in the brains of skin homogenate-inoculated mice were also similar to those of brain homogenate-inoculated mice (Fig. 4, D and E) . By contrast, all seven TgWV mice inoculated with normal skin homogenate from a non-CJD patient carrying the 129V/V genotype of PrP were overweight, but none of the mice became infected, and no PrP Sc was detected in any of the mice at 564 dpi (Fig. 4, C and E) . In addition, TgNN6h control mice that were not inoculated exhibited a normal life span and did not display any obvious abnormal phenotypes.
DISCUSSION
Our study demonstrates the presence of prion infectivity, seeding activity, and, in one case, PK-resistant PrP Sc in the skin of sCJD patients. Although we have not completed the direct comparison of the infectivity of PrP Sc from sCJD brain and skin by bioassay in humanized Tg mice, our RT-QuIC assays indicated that prion seeding activity was approximately 1000-fold lower in the skin than in the brain of the same patient. These seed concentrations are similar to those found in nasal brushings from CJD patients (26) . Given the observed partial correlation between seeding activity and infectivity (14, 27) , we predict that sCJD infectivity is also orders of magnitude lower in the skin than in the brain of CJD patients.
The tissue distribution of prions can differ markedly between prion diseases, and prion detection in various tissues depends in part on the sensitivity of the assays used. For example, using Western blot analysis, PrP
Sc was found to be more widely distributed in the periphery of 
Non-CJD
Specificity (%) 100 100 100 100 ¶ *Weak positive (+/−) means one of four or two of eight wells on two or more independent experiments. †Positive (+) RT-QuIC prion seeding activity.
‡Negative (−) RT-QuIC prion seeding activity. §RT-QuIC analysis of skin samples from the torso or forearm of the UK vCJD and US vCJD patients, respectively, was RT-QuIC-positive and was included in the overall sensitivity and confidence interval calculations.
¶RT-QuIC analysis of skin samples from the torso or forearm of eight non-CJD patients was RT-QuIC-negative and was included in the overall specificity and confidence interval calculations. patients with vCJD than sCJD patients (28, 29) . However, using the more sensitive RT-QuIC assay, sCJD seeding activity was recently detected in nonneuronal tissues such as the spleen, kidney, lung, liver, and adrenal glands of four sCJD patients (30) . We have detected roughly comparable RT-QuIC prion seeding activity, as well as prion infectivity, in the skin of cases with two sCJD subtypes (MM2 and VV1). Whether PrP Sc in skin from cases of the most common sCJD subtype (MM1) is also transmissible to experimental animals remains to be determined; however, our RT-QuIC analyses indicated at least equivalent seeding activity in sCJDMM1 skin (Table 3) . Our current results raise concerns about iatrogenic transmission of prions harbored in sCJD skin. For example, the presence of transmissible skin prions raises the question of the presence of other possible iatrogenic routes of CJD, although the epidemiologic evidence for this varies widely and has largely been inconclusive (5) (6) (7) (8) (9) (10) (11) .
We should emphasize that in no way does our study imply that prion transmission can occur via casual contact. The bioassays that we have performed involved inoculation of relatively large amounts of skin extracts directly into the brains of humanized Tg mice, which is not likely to be recapitulated in humans in any sort of routine event. Prion transmission from skin in humans, if even possible, likely requires additional specific inoculation scenarios that have existed in documented iatrogenic transmissions of human prion disease, that is, CNS injection, hematogenous spread, or oral consumption with sufficient quantities of infectious material (4). The apparent rarity of such scenarios in routine clinical care may be responsible for the lower than expected hazard ratios of certain procedures discussed in some epidemiological studies compared to the much higher risks associated with known modes of iatrogenic CJD transmission. In addition, the rate of skin-associated transmission, if present, would likely be much lower than that of CNS-associated transmission, given the much lower RT-QuIC prion seeding activity in the skin than in the brains of sCJD cases. Nevertheless, further scrutiny is necessary to determine whether extra precautions should be taken during non-CNS surgeries of sCJD patients, especially in the case of procedures where surgical instruments are reused.
As noted above, the detection of prions and PrP Sc in skin is not altogether unprecedented. PrP
Sc has been detected in the skin of experimentally or naturally scrapie-infected hamsters and sheep (13) , as well as in the skin of a single patient with vCJD (12) . Prion infectivity has also been reported in the skin of infected greater kudu (31) . In addition, mouse prion inoculation by skin scarification has been found to have almost the same efficiency as inoculation by the intraperitoneal, intravenous, or perivenous routes (32) . The inoculated prions first propagate in the skin and then spread to the brain to cause prion disease (33, 34) . All of these modes of prion spread between the brain and the skin are believed to occur via the peripheral nervous system. PrP Sc has been detected in the trigeminal ganglion in sCJD and vCJD patients by immunohistochemistry and Western blotting (35) and in the nerve fibers within the skin of hamsters inoculated with the 263K prion strain by immunohistochemistry (13) . The dermatomes examined in our study including the skull apex, the area near the ear, the forearm, and the lower back are innervated by the oculomotor nerve III ophthalmic division, cervical nerves 2 to 3 (C2-3), C5, or thoracic nerves 10 to 11, respectively. It is possible that prions spread from the brain to the dermatomes through these spinal nerves.
In conclusion, we have detected prions in the skin of the sCJD cases that we have tested but not in non-CJD control individuals. However, our study does not establish when and where within the skin prions appear in the course of disease. Moreover, other than the indication that prion seeding activity is~1000-fold lower in the skin than in brain tissue, our data do not clarify the basis of seemingly divergent epidemiologic reports on sCJD risks, or lack thereof, associated with surgical procedures involving the skin. We have not yet validated that RT-QuIC Fig. 3 . RT-QuIC testing of prion seeding activity in P4 skin fractions from sCJD and vCJD patients. P4 skin fractions from the sCJD and vCJD patients were analyzed using a second rPrP sen substrate, hamster rPrP sen (residues 23 to 231), which has been previously shown to help discriminate between these two human prion strains (21) .
) of P4 skin fractions from four sCJD patients (nos. 1, 2, 4, and 5) and 1 vCJD patient (no. 6) were used to seed quadruplicate RT-QuIC reactions. Testing was performed using either bank vole rPrP sen in the presence of 300 mM NaCl and 0.001% SDS (A) or hamster rPrP sen in the presence of 300 mM NaCl and 0.002% SDS (B). Testing was performed twice with similar results. The data show the average fluorescence of replicate wells monitored over time. *Log seeding dose 50 (SD 50 ) was calculated, as described in Materials and Methods. Fig. 4 . Prion infectivity of skin samples from sCJD patients. (A) Survival curves of TgNN6h or TgWV humanized Tg mice inoculated with skin homogenate from sCJD or non-CJD patients. Six-to 8-week-old TgNN6h (n = 5) or TgWV (n = 7) mice were intracerebrally inoculated with 30 ml of 5% skin homogenate from patients with sCJDMM2 or sCJDVV1. Five TgNN6h mice were intracerebrally inoculated with skin homogenate from a patient with sCJDMM2 (red diamonds), and seven TgWV mice were intracerebrally inoculated with skin homogenate from a patient with sCJDVV1 (blue squares). Seven TgWV mice were intracerebrally inoculated with skin homogenate from a non-CJD patient as a negative control (green line analysis of skin would have practical utility in the diagnosis of sCJD. Further studies are needed to clarify the risks associated with skin samples from sCJD patients and to increase our understanding of prion transmissibility.
MATERIALS AND METHODS
Study design
The aim of the study was to determine whether there are infectious prions in the skin of sCJD patients. The skin samples were collected at autopsy or biopsy from different body areas of 38 patients including 21 sCJD, 2 vCJD, and 15 non-CJD. The abnormal PrP from the skin was enriched by ultracentrifugation before Western blotting analysis. Moreover, concentrated or unconcentrated PrP from skin and brain samples was further subjected to the highly sensitive RT-QuIC assay in a blinded fashion. Finally, to determine whether the sCJD skin is infectious, we conducted a bioassay with two lines of humanized Tg mice inoculated intracerebrally with skin homogenates from two sCJD patients and one non-CJD patient. In addition to monitoring the clinical signs of the inoculated animals, the brain samples of the mice were examined by Western blotting and neurohistology. Samples were collected randomly according to the diagnosis by Western blotting and histology. All data on Western blotting and RT-QuIC assay of human brain and skin samples were repeated at least two to three times. To ensure that the bioassay data were reliable, we used two different sCJD cases and one non-CJD case, as well as two different humanized Tg mouse models. Skin tissues and preparation Thirty-five of the 38 skin samples were obtained at autopsy, and the remaining three samples were biopsied. The skin samples (~60 to 80 mg each in weight,~6 mm × 6 mm each in size) contained all three layers including epidermis, dermis, and hypodermis from different parts of the body such as the apex, area next to left ear (~1 cm away from the ear), forearm, chest, lower back, and knee. During the autopsy process, special care was taken to assure that there was no cross contamination between the skin and the brain samples and from case to case. All skin tissues were taken before the skull was opened. The instruments were either virgin or used only for collecting skin after decontamination each time. The autopsied or biopsied tissues were taken at nine different facilities and frozen in dry ice first and then transferred to a freezer at −80°C. The frozen skin samples were prepared for Western blot analysis probing with anti-PrP antibody 3F4 or anti-C against human PrP(220-231) (12, 13, 18, 36) , for RT-QuIC analysis (14) , or as inocula for bioassay, as described previously (15) with minor modifications (see the Supplementary Materials for details).
Molecular genetic analysis
These analyses were performed on genomic DNA, as described previously (15, 38) and in the Supplementary Materials.
RT-QuIC analysis
The RT-QuIC analysis of skin or brain samples was conducted, as described previously (14, 21, 26, 37) and in the Supplementary Materials.
Generation, screening, and characterization of Tg humanized TgWV and TgNN6h mice The generation of Tg mice expressing human PrP-129V or PrP-129M from transgene constructs based on the murine half-genomic PrP clone in plasmid pHGPRP was performed, as described previously (15, 24, 25) and in the Supplementary Materials.
Humanized Tg mouse-based bioassay of skin or brain samples from sCJD patients Infectivity of sCJD skin samples was evaluated by intracerebral inoculation of TgNN6h or TgWV mice with 5% skin tissue homogenate from one patient with sCJDMM2 or sCJDVV1, respectively. The reason that the two lines of humanized Tg mice were chosen for testing the two sCJD skin samples was because our preliminary study exhibited that they were highly susceptible to the 129 polymorphism-matched sCJD brain inocula. After anesthetization with isoflurane, 30 ml of 5% skin homogenate or 30 ml of 1% brain homogenate (in phosphate-buffered saline) was injected into each mouse intracerebrally with a 26-gauge needle inserted to a depth of 4 mm at the left parietal region of the cranium, as described previously (15) . The mice were monitored for prionrelated signs such as hunched back, ruffled fur, rigid tails, and slow movement every other day and sacrificed within 3 days after the appearance of severe signs or at death. The brains were collected and sliced sagittally-half of which was frozen for Western blotting with the antiPrP antibody 3F4 (18, 36) , and the other half was fixed in 10% formalin for histological and immunohistochemical staining analysis (see below). Total PrP, as well as PK-treated PrP Sc , was determined by immunoblotting in SDS-polyacrylamide gels, as described in the Supplementary Materials.
Statistical analysis
Statistical comparisons of mean relative ThT fluorescence responses in samples from CJD and non-CJD patients were performed using unpaired Student's t tests.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/9/417/eaam7785/DC1 Methods Fig. S1 . Western blotting and neurohistology of autopsy brain samples from sCJD and vCJD patients. Fig. S2 . Representative immunohistochemistry of skin samples from two vCJD patients and a non-CJD patient. Fig. S3 . Representative RT-QuIC end-point dilution analysis of brain and skin fractions from two CJD patients. Fig. S4 . Western blot analysis of bank vole rPrP res RT-QuIC products from reactions seeded with brain or skin samples. Fig. S5 . Western blot analysis of brain samples from TgNN6h or TgWV mice inoculated intracerebrally with sCJDMM2 or sCJDVV2 brain homogenate, respectively. Table S1 . Summary of non-CJD cases.
